AR002947A1 - Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion - Google Patents

Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion

Info

Publication number
AR002947A1
AR002947A1 ARP950100500A AR10050095A AR002947A1 AR 002947 A1 AR002947 A1 AR 002947A1 AR P950100500 A ARP950100500 A AR P950100500A AR 10050095 A AR10050095 A AR 10050095A AR 002947 A1 AR002947 A1 AR 002947A1
Authority
AR
Argentina
Prior art keywords
composition
stimulant
xantina
preparing
controlled release
Prior art date
Application number
ARP950100500A
Other languages
English (en)
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of AR002947A1 publication Critical patent/AR002947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Una composición para la liberación controlada de una estimulante de xantina o un derivado de xantina, que comprende micropartículas que incluyen una matrizbiodegrable de por lo menos un material soluble en agua y el estimulante, estando dicho estimulante en forma de partículas sólidas que estánsubstancialmente distribuidas uniformemente a través de toda la matriz. Además, se da a conocer un método para preparar esta composición mediante la dispersióndel estimulante en forma de una pluralidad de partículas en una matriz biodegradable. Dicha composición puede administrarse ventajosamente en formaoral aumentando el estado de alerta de un individuo.
ARP950100500A 1994-12-16 1995-12-11 Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion AR002947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/357,689 US5744164A (en) 1994-12-16 1994-12-16 Sustained release microparticulate caffeine formulation

Publications (1)

Publication Number Publication Date
AR002947A1 true AR002947A1 (es) 1998-05-27

Family

ID=23406640

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP950100500A AR002947A1 (es) 1994-12-16 1995-12-11 Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion

Country Status (21)

Country Link
US (2) US5744164A (es)
EP (2) EP0716853A1 (es)
JP (1) JPH10510529A (es)
AR (1) AR002947A1 (es)
AT (1) ATE201986T1 (es)
AU (1) AU694810B2 (es)
CA (1) CA2208149C (es)
CO (1) CO4600671A1 (es)
DE (1) DE69521328T2 (es)
DK (1) DK0789562T3 (es)
ES (1) ES2158956T3 (es)
GR (1) GR3036501T3 (es)
HK (1) HK1000878A1 (es)
IL (1) IL116066A (es)
NZ (1) NZ295245A (es)
PE (1) PE55396A1 (es)
PT (1) PT789562E (es)
RU (1) RU2144353C1 (es)
TR (1) TR199501560A2 (es)
WO (1) WO1996018389A1 (es)
ZA (1) ZA9510687B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000674A1 (en) * 1995-06-20 1997-01-09 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
WO2001021147A1 (en) * 1999-09-20 2001-03-29 Mastercare Diet and weight control gum and sucker
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US7897141B2 (en) * 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US20030220351A1 (en) * 2002-05-24 2003-11-27 Gilbert Gonzales Enteric coated caffeine tablet
AU2003292110A1 (en) * 2002-11-25 2004-06-18 Phares Pharmaceutical Research N.V. Confectionery composition
US20050181044A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
US20050220875A1 (en) * 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
EP2389174A4 (en) * 2009-01-22 2014-05-07 Abbot Healthcare Private Ltd PHARMACEUTICAL COMPOSITION FOR CHRONOTHERAPY
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
US8992898B2 (en) 2010-04-17 2015-03-31 Shannon Elizabeth Klingman Antiperspirants and deodorants
WO2014197601A1 (en) * 2013-06-04 2014-12-11 KVK-Tech, Inc. Controlled release caffeine dosage forms
JP2018504454A (ja) 2015-01-12 2018-02-15 ナノ ファーマシューティカル ラボラトリーズ エルエルシーＮａｎｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌａｂｏｒａｔｏｒｉｅｓ ＬＬＣ 積層徐放型マイクロビーズ及びその作製方法
KR101644154B1 (ko) * 2015-09-08 2016-07-29 주식회사 스킨앤테크 수용성 카페인 및 그 제조방법
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
US20220288083A1 (en) * 2021-03-09 2022-09-15 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
EP4378456A1 (en) * 2021-07-30 2024-06-05 Panion & BF Biotech Inc. Controlled-release oral preparation and preparation method therefor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265629A (en) * 1958-12-22 1966-08-09 Ncr Co Coating by phase separation
DE1249219B (de) * 1958-12-22 1967-09-07 The National Cash Register Company, Dayton, Ohio (V. St. A.) Herstellen von Mikrokapseln, die eine Emulsion aus Öl in hydrophiler Flüssigkeit enthalten
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4001480A (en) * 1974-08-16 1977-01-04 Swift & Company Encapsulation process utilizing microorganisms and products produced thereby
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
NZ207813A (en) * 1983-06-24 1986-12-05 Dridrinks Nv Effervescent mixture:component(s)coated with water-soluble polysaccharide composition
DE3474099D1 (en) * 1983-06-24 1988-10-27 Dridrinks Nv Treatment of acids as compounds of water-soluble, powdery compositions intended for preparing beverages with lasting gaseous delivery.
NZ210785A (en) * 1984-01-13 1987-11-27 Battelle Development Corp Liquid dispersions of layered controlled release dosage forms
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
DE3537770A1 (de) * 1985-10-24 1987-04-30 Basf Ag Salze mehrwertiger kationen von polymerisaten von konjugierten dienen
US4853249A (en) * 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
AU7280387A (en) * 1986-04-07 1987-11-09 Rorer International (Overseas) Inc. Method for the preparation of a sustained release pharmaceutical composition and the compostion prepared thereby
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4971785A (en) * 1988-03-14 1990-11-20 Spectrum Consumer Products Co., Inc. Non-alcoholic delivery system for orally ingestible active ingredients
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤

Also Published As

Publication number Publication date
PT789562E (pt) 2001-10-30
EP0716853A1 (en) 1996-06-19
DE69521328D1 (de) 2001-07-19
ZA9510687B (en) 1996-07-03
IL116066A0 (en) 1996-01-31
AU694810B2 (en) 1998-07-30
PE55396A1 (es) 1996-12-24
IL116066A (en) 2000-10-31
CO4600671A1 (es) 1998-05-08
EP0789562A1 (en) 1997-08-20
HK1000878A1 (en) 2001-10-26
US5700484A (en) 1997-12-23
CA2208149A1 (en) 1996-06-20
NZ295245A (en) 1999-01-28
ES2158956T3 (es) 2001-09-16
US5744164A (en) 1998-04-28
JPH10510529A (ja) 1998-10-13
CA2208149C (en) 2007-03-27
DE69521328T2 (de) 2002-01-17
RU2144353C1 (ru) 2000-01-20
AU3854295A (en) 1996-07-03
DK0789562T3 (da) 2001-09-03
EP0789562B1 (en) 2001-06-13
ATE201986T1 (de) 2001-06-15
GR3036501T3 (en) 2001-11-30
WO1996018389A1 (en) 1996-06-20
TR199501560A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
AR002947A1 (es) Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion
CY1106112T1 (el) Σταθepοποιημενες συνταγοποιησεις παρατεταμενης απελευθερωσης tramadol
GB9416600D0 (en) Pharmaceutical formulation
ES2029269T5 (es) Una formulacion de liberacion lenta.
BR0314958A (pt) Composição reativa de fóton múltiplo, artigo e método para fabricar um compósito orgânico-inorgânico
MX9201141A (es) Ciclosporinas cristalinas, procedimiento para su produccion y composicion farmaceutica que las contiene.
AR002754A1 (es) Composición farmacéutica que comprende bacterias lactobacillus viables micro-encapsuladas, y uso de la composición para preparar de un medicamento
BR9100435A (pt) Composto,composicao farmaceutica,uso,metodo de tratamento de um animal,processos para a preparacao da um composto e de uma composicao farmaceutica
MX9304975A (es) Una composicion en polvo para inhalacion y procedimiento para preparar la misma.
AR018252A1 (es) Forma de dosificacion farmaceutica en particulas solidas adecuada para suministro oral.
IL123505A0 (en) Sustained release matrix for high-dose insoluble drugs
DE69318415D1 (de) Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
AU8227291A (en) Therapeutical composition and process for its preparation
AR012717A1 (es) Trihidrato de la sal de magnesio de s-omeprazol, proceso para su preparacion, composicion farmaceutica, y uso de dicho trihidrato para la fabricacion de medicamentos.
ES2195220T3 (es) Acidos sulfonilaminocarboxilicos.
ES2165640T3 (es) Acidos diaminocarboxilicos sustituidos.
AR017079A1 (es) Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.
CR5524A (es) Formulaciones y usos del repelente de insectos de liberación lenta
PT1113787E (pt) Preparados farmaceuticos de libertacao controlada sob a forma de unidades multiplas independentes da agitacao e processo para preparacao dos mesmos
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
DE69941996D1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
AR043070A1 (es) Sistema monolitico que contiene una o mas drogas, formado por tres capas con diferentes mecanismos de liberacion
IT1230703B (it) Derivati imidazolonici ad attivita' antiipertensiva, loro metodi di preparazione e composizioni farmaceutiche che li contengono.
BR9814751A (pt) Composição sólida seca para liberação de droga, processo para a preparação da mesma, e, uso de um grande número de partìculas porosas inorgânicas que são compostas de hidroxiapatita de cerâmica.
ES2183172T3 (es) Procedimiento para la preparacion de microparticulas.